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Abstract  
This study assessed the subjective experience of participating in a clinical trial, specifically positive and 
negative experiences and the experience of audio recording assessment sessions. The study was cross-
sectional from a single blinded randomised controlled trial. Forty participants with a primary diagnosis of 
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non-organic psychosis completed baseline and 12-week follow-up questionnaires assessing their 
experiences. Participants rated research interviews as moderately helpful in facilitating their therapy and 
talking to the interviewer as moderately helpful at baseline and 12-week follow-up. Self-report ratings of the 
degree of self-realisation promoted by the research questionnaires were significantly higher at 12-week 
follow-up compared to baseline. Participants adjusted quickly to being audio recorded and rated interviews 
as not at all disruptive and not at all to slightly intrusive. On average there were neutral emotional reactions, 
positive gains and minimal inconveniences as a result of participation. The main reasons for taking part 
were: ‘To help myself’, ‘I was curious’ and ‘To help others’. The findings offer support to previous research 
reporting that individuals with mental health problems find participating in clinical trials a beneficial 
experience. This may alleviate concerns that participation in similar studies may be personally intrusive or 
harmful.  
 
Keywords: positive, negative, participate, research, mental health, audio recording 
 
1. Introduction  
Research involving human participants has been a longstanding topic for ethical, legal and methodological 
discussion (Braunack-Mayer, 2002; Cassileth et al., 1982; Taylor et al., 2010). However, there has been 
limited research documenting the effects of psychiatric research procedures on participants (Kassam-Adams 
and Newman, 2002) as well as the perceptions of the participants involved (Grant, 2015; Marshall et al., 
2001; Schäfer et al., 2008). There is an identified need for the development of new instruments assessing 
participants’ experiences of treatment research in order to ensure the protection of participants and the 
integrity of the research methods employed (Marshall et al., 2001).     
Recruiting eligible participants for clinical trials has often proven to be very difficult (Campbell et al., 
2007). However, trial participants play a major role in the development of effective new treatments (Harris 
et al., 1996) and provide evidence that helps inform treatment options for patients (Tallon et al., 2011). 
These studies rely on recruiting large numbers of participants (Marshall et al., 2001) and are dependent on 
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timely recruitment and retention of participants (Tallon et al., 2011). Moreover, the way in which research 
participants experience associated benefits and risks can be a complex issue (Braunack-Mayer, 2002). 
Individuals may decide to participate in research for a number of reasons such as feeling a sense of 
obligation, hoping to receive some benefit or wanting to help others (Braunack-Mayer, 2002). 
Therefore, it is important to understand the perceptions of potential participants (Marshall et al., 2001) and 
their readiness to participate (Roberts et al., 2006) when designing and conducting successful trials that are 
acceptable to the target population (Tallon et al., 2011). Furthermore, it is important to document their 
experience of research which may also help to assess the quality and validity of research findings (Newman 
et al., 2001).  
The AVATAR Clinical Trial aims to test the clinical efficacy of the AVATAR therapy in reducing the 
frequency and severity of auditory verbal hallucinations (Craig et al., 2015). It involves completing a 
number of measures at baseline, 12 weeks and 24 weeks follow-up. The assessment sessions are audio-
recorded with the participant’s consent and participants are randomly allocated to be invited to attend seven 
weekly therapy sessions in both arms of the trial. Main results have been recently published, showing that 
AVATAR therapy resulted in a rapid and substantial fall in the frequency, omnipotence and power of 
voices, and associated distress that was significantly superior to supportive counselling at 12 weeks follow-
up. At 24 weeks follow-up the differences between the two arms were no longer statistically significant. 
Reductions in the AVATAR therapy scores on primary outcome were sustained and the absence of 
statistically significant between group differences at 24 week follow-up relates to the supportive counselling 
group continuing to improve between 12 and 24 week follow-up. There was no evidence of any adverse 
events attributable to either therapy (Craig et al., 2017).  
It is known that clinicians tend to overestimate the negative impact of research participation and 
underestimate the potential  positive benefits (Marshall et al., 2001; Newman et al., 2001). It has also been 
noted that negative reactions from participants tend to be rare (Jorm et al., 2007; Taylor et al., 2010), with 
psychosocial research assessing the role of traumatic events more likely to be approved by patients rather 
than biological research (Schäfer et al., 2008). Although some participants may find it distressing to talk 
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about the experience of voices and previous traumatic events, they may also find it beneficial to address 
these topics in a supportive environment (Braunack-Mayer, 2002). It is therefore of interest to assess the 
impact of participating in the AVATAR Clinical Trial and to understand the associated benefits by asking 
the participants involved. Little is also known about the impact of audio recordings in research and practice 
despite its widespread use (Briggie et al., 2016).   
 
1.2. Aim 
To assess the subjective experiences of participants involved in the AVATAR Clinical Trial, specifically the 
positive and negative experiences of the research as well as the experience of audio recording assessment 
sessions. The study also aims to ascertain participants’ motivation for taking part and to establish the 
internal consistency of the measures used.   
2. Methods 
The AVATAR (Audio Visual Assisted Therapy Aid for Refractory auditory hallucinations)  study is a 
single blinded randomised controlled trial assessing the effectiveness of a new computer assisted therapy to 
help reduce the frequency and severity of auditory hallucinations (Craig et al., 2017). Participants who met 
the eligibility criteria were randomly allocated to receive AVATAR therapy (intervention group) or 
supportive counselling (control group). Both therapies were delivered over 7 sessions (1 introductory session 
plus 6 therapy sessions) lasting approximately 45 minutes. Participants were also required to complete 
weekly in-session measures with the therapists. Therapy sessions were audio-recorded and participants were 
provided with an MP3 player and given instructions to listen to their sessions in between therapy.  
The research element of the AVATAR study involved participants completing assessments at three time 
points: at baseline (before randomisation), 12 weeks and at 24 weeks follow-up. These assessments included 
a number of interview-based and self-report measures to assess the impact of the interventions on specific 
outcomes. Research assessments were also audio-recorded (with participant’s permission), lasted 
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approximately 1.5 hours and participants were paid £20 for each assessment as a reimbursement for their 
time.  
 
2.1. Participants 
Participants were eligible for the present study if they completed the baseline assessment, attended at least 
one session of either intervention, and the 12-week follow-up assessment. They were not given any 
additional reimbursement for completing the questionnaires in this study. 
2.2. Measures 
The Assessing the Impact of Research Questionnaire (AIR; (Marshall et al., 2001)) is a 14-item (baseline 
evaluation) and 19-item (follow-up evaluation) self-report measure employing a Likert-type scale to assess 
positive and negative emotional and cognitive appraisals of experiences of completing structured interviews, 
questionnaires and having sessions audio-recorded.  There were minor adaptations to the wording to make 
the questionnaire relevant to the specific time points being assessed in this study. One item assessing the 
specific number of audio-recorded sessions it took for participants to feel comfortable (“How many tape-
recorded sessions did it take for you to feel as comfortable as you usually do?”) was not applicable and 
therefore omitted. The final version of the AIR used at baseline consisted of 13 items; four assessing 
positive impacts (e.g. promoting self-realisation - where participants realise something new about 
themselves), four assessing negative impacts (e.g. disruptiveness or intrusiveness of interviews) and five 
items assessing difficulty adjusting to audio recording. (Note: Impact refers to participants’ appraisals of 
experiences rather than inferring a causal role). The final version of the 12-week follow-up evaluation 
consisted of 20 items with the addition of an item about keeping the researchers ‘blinded’ about the type of 
therapy received. Participants were also given the opportunity to leave free text comments about their 
overall experience. The AIR was scored by calculating the means and frequencies of individual items and 
required interpretation on an individual basis. The internal consistency of this measure has not yet been 
published and will be established in the present study.   
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The Reactions to Research Participation Questionnaire (RRPQ; (Newman et al., 2001)) is a 23-item self-
report measure rated on a 5 point Likert scale (from 1 - ‘Strongly disagree’ to 5 - Strongly agree). It was 
developed to assess participants’ evaluation of research participation and was designed to be applicable to a 
wide range of research areas. There are five subscales: participation factor, personal benefits, emotional 
reactions, perceived drawbacks and global evaluation. Scores for the RRPQ were calculated by computing 
the averages of the items loading on to each subscale. The emotional reactions subscale was used at the 
baseline evaluation to assess initial reactions, whilst the full scale was used at the 12-week follow-up 
evaluation to assess the overall impact of the study. Good psychometric properties have been reported for 
this measure (Kassam-Adams and Newman, 2002; Murphy et al., 2011; Newman et al., 2006). A cross-
sectional study of women’s reactions to body image and eating disorder research reported good reliability 
for the emotional reactions  (α = 0.86), personal benefits (α = 0.82), perceived drawbacks (α = 0.73) and 
global evaluation (α = 0.77) sub-scales (Murphy et al., 2011). The internal consistency of the participation 
factor subscale was 0.6 (Murphy et al., 2011).  The RRPQ also includes a checklist which asks participants 
to rank their top three reasons for taking part in the study out of a possible nine reasons. This list included 
reasons such as “I was curious”, “I felt I had to” and “For the money”.  
2.3. Procedure 
The 13-item baseline AIR evaluation together with the emotional reaction subscale of the RRPQ and the 
checklist of reasons for participating were completed after the baseline assessment. The 20-item 12-week 
follow-up AIR evaluation and 23-item RRPQ were completed after the 12-week follow-up assessment. The 
questionnaires primarily focused on participants’ experience of the research assessments rather than 
experience of therapy sessions. However, there were questions in the 12-week follow-up evaluation which 
asked participants whether the research experience was discussed in therapy sessions and the helpfulness of 
discussing this experience as part of assessing the impact of the research. 
In order to prevent ‘unblinding’ of the researchers, the trial coordinator reviewed the returned questionnaires 
before passing them on for data entry. 
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The study data collection took place between January 2015 and January 2016, concurrently with recruitment 
for the AVATAR study (from November 2013 to February 2016). Participants who completed the baseline 
and 12-week follow-up assessments during this period (n =75) were asked at the end of each session 
whether they would be interested in completing a short questionnaire about their experience of taking part in 
the research. If agreeable, they were provided with a copy of the relevant questionnaire (baseline or 12-week 
follow-up) with a stamped addressed envelope to be completed at home without the researcher present and 
returned within one week. The aim was to obtain an adequate sample size of baseline and follow-up 
responses, with the possibility of some participants completing both questionnaires.   
2.4. Data analysis  
Data were analysed using SPSS version 21. The positive and negative impacts of the research at baseline 
and 12-week follow-up were reported using means, standard deviations, frequencies and percentages. RRPQ 
scores were also reported descriptively. Percentages for the reasons for participating were calculated by 
summing the frequencies of the top three reasons on the checklist. Given the small sample size and the non-
normal distribution of the data, the non-parametric Wilcoxon Signed Ranks test was used to investigate any 
differences between baseline and 12-week follow-up for those participants who completed surveys at both 
time points (n = 10).  
2.4.1. Internal consistency  
In the present study, the internal consistency of the AIR was assessed using Cronbach’s alpha, with a 
criterion of 0.70 taken as indicating good internal consistency (Streiner et al., 2014). The reliability of the 
five subscales of the RRPQ was also calculated and reported using the same criterion.  
3. Results  
A total number of 54 participants agreed to take baseline questionnaires and 41 agreed to take 12-week 
follow-up questionnaires for completion in their own time out of the 75 participants approached (72% and 
55% response rate respectively). Of these, 31/54 baseline questionnaires (57%) and 19/41 12-week follow-
up evaluations (46%) were returned. All respondents had a primary diagnosis of non-organic psychosis 
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including paranoid schizophrenia, schizoaffective disorder and bipolar disorder. The sociodemographic and 
clinical characteristics of all participants are shown in Table 1. A majority of the respondents were male 
(65%), single (72.5%) and not currently in employment (85%).  The mean age was 44.34 years (S.D. = 9.87) 
and most (75%) had at least secondary (O Level/GCSE equivalent) qualifications. There were no differences 
between participants in the present study and those in the main AVATAR Clinical Trial (n = 150; Craig et 
al., 2017) in terms of the sociodemographic and clinical characteristics reported below indicating a 
representative sample.   
[Insert Table 1 about here] 
 
3.1. Internal consistency 
The internal consistency of the 13-item baseline AIR employed in this study was 0.61. The 12-week follow-
up measure demonstrated good reliability with an alpha of 0.7. The emotional reactions subscale employed 
at baseline had good internal consistency (α = 0.83). The internal consistencies for the five subscales at 12-
week follow-up were: participation factor (α = 0.65), personal benefits (α = 0.82), perceived drawbacks (α = 
0.75), global evaluation (α = 0.84) and emotional reactions (α = 0.85).  
3.2. Impact of the research 
Table 2 displays the means and standard deviations for each item assessing the positive and negative impacts 
at baseline and 12-week follow-up. Categorical endorsements for each item are shown in Table 3. On 
average, participants rated completing the research questionnaires at baseline as slightly to moderately 
helpful in realising something new about themselves and moderately helpful at 12-week follow-up. 
Additionally, participants at both baseline and 12-week follow-up rated the research interviews as 
moderately helpful in facilitating their therapy in some way and found it moderately helpful to talk to 
research interviewers about themselves. Overall, participants rated that they were moderately personally 
helped by taking part in the research. 
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The research questionnaires and interviews at baseline and 12-week follow-up were rated as not at all to 
slightly irrelevant to commencing therapy and not at all to slightly a negative experience. The research 
interviews at baseline were rated as slightly intrusive whilst at 12-week follow-up they were rated as not at 
all to slightly intrusive. At both time points the research interviews were rated as not at all disruptive to the 
therapy received (82.8% endorsements in ‘Not at all’ category at baseline; 93.8% at 12-week follow-up). 
Overall, participants reported that completing the research assessments did not interfere with their therapy at 
all and rated their overall experience as not at all personally intrusive or harmful.  
Adjustments to the audio-recording occurred right away to very soon (70% endorsement in these 
categories). There was little difficulty adjusting to being audio recorded, with a majority (90%) endorsing 
the ‘not at all’ and ‘slightly’ categories. Participants also found it slightly to moderately helpful or reassuring 
to have the sessions audio recorded. Of particular note, the presence of the recorder did not seem to interfere 
with thoughts shared with the researcher, with 80.6% reporting no interference at all.  
For those participants who completed questionnaires at both time points (n = 10), self-report ratings of the 
degree of self-realisation promoted by the questionnaires were significantly higher at 12-week follow-up 
(Mean = 3.4; S.D. = 0.97) compared to baseline (Mean = 2.75; S.D. = 1.17) (Z = -2.06; p = 0.039). Further 
investigation revealed that 9/10 of these participants completed all therapy sessions (n = 7) and a majority 
(60%) reported at 12-week follow-up that discussion of their research experience during therapy sessions 
promoted new insight about themselves. There were no other statistically significant changes between 
baseline and 12-week follow-up evaluations on any other variable examined.     
Some participants (52.6%) did not go on to discuss their research experience during therapy sessions and 
some (57.9%) also reported that there was nothing that was revealed in the research assessments that was not 
otherwise discussed in therapy. A majority (71.4%) went on to eventually discuss things revealed in research 
during therapy.  
Overall participants found it slightly difficult to conceal their therapy allocation in order to keep researchers 
‘blinded’ (Mean = 2; S.D. = 1.31). When asked about informed consent, almost all participants (17 of 19) 
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felt they were well informed about the research study prior to agreeing to participate. A majority of 
participants (73.7%) reported that they would definitely or probably participate in this research if they had to 
do it over again. Examination of the free texts comments indicated good experiences overall. Participants 
found the research to be helpful, interesting and beneficial. Some appreciated being given the opportunity to 
talk to someone about current experiences and distress in their lives in a comfortable, safe and non-
judgemental environment. Others reported that the research helped to ease worries, helped with their illness 
or with moving on with their lives in general. Examples of comments related to the research interviews 
include:  
“I felt comfortable doing the research. The interviewer has a nice trustworthy attitude which made me feel 
safe and able to talk.” 
“The person I spoke with in sessions was easy to get along with and I felt she didn't judge me, which 
allowed me to be open and honest.” 
“I found it slightly stressful but helpful” 
[Insert Table 2 about here] 
[Insert Table 3 about here] 
3.3. Participant reactions  
From the checklist provided, participants indicated that they took part in the clinical trial for the following 
reasons: “To help myself” (65%), "I was curious” (45%), “To help others” (25%), “Thought it might 
improve my access to health care” (20%), “I don’t know” (15%), “For the money” (7.5%), “I didn’t want 
to say no” (7.5%), and “Felt I had to” (5%). (Percentage sums are greater than 100 as participants could 
select more than one reason.)       
Scores on the emotional reactions subscale at baseline were around 3 (Mean = 2.84; S.D. = 1.06; n = 31) 
indicating neutral agreement with the statements pertaining to negative emotional reactions caused by the 
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study. Descriptive statistics for the five subscales of the RRPQ at 12-week follow-up are described in Table 
4.  
Scores on all three positive factors (participation, personal benefits and global evaluations) at 12-week 
follow-up were greater than 4 indicating agreement with statements pertaining to positive gains and 
experiences from the study.  Scores on the perceived drawbacks factor were around 2, indicating 
disagreement with statements relating to inconveniences that may have been caused by the study. Finally, 
scores on the emotional reaction subscale at 12-week follow-up were around 3 (Mean = 3.12; SD = 1.13) 
indicating neutral agreement with the statements pertaining to negative emotional reactions.    
[Insert Table 4 about here] 
4. Discussion  
This study aimed to investigate the subjective experiences of participants in a clinical trial assessing the 
efficacy of a new computer assisted treatment (AVATAR therapy). It also aimed to describe the positive and 
negative impacts, participants’ motivation for taking part and their reactions to research participation. The 
findings indicate minimal negative impacts from participating in the trial and a moderate positive impact. 
These findings mirror those from another clinical trial in which similar impacts were reported (Marshall et 
al., 2001). Self-report ratings of the degree of self-realisation promoted by completing research 
questionnaires were significantly higher at 12-week follow-up compared to baseline for those who 
completed this study at both time points. Additionally, most of these participants reported that they had 
realised something new about themselves through discussing their research experience during therapy 
sessions.  
Concealing therapy allocation from researchers was identified as a challenge for some participants in the 
AVATAR Clinical Trial. There was little difficulty in adjusting to being audio-recorded, with participants 
rating the presence of the recorder as slightly to moderately reassuring. It is important to note that initial 
assessments included questions about childhood trauma (Bernstein et al., 2003) and voice experiences 
including verbatim content. In most instances recording did not affect the level of information disclosed or 
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thoughts shared with the researcher (although in a minority of cases where the person was reluctant to 
discuss, for example, distressing voice content it was agreed that this could be done directly with the 
therapist).  The experience of paranoid thoughts and persecutory beliefs are a frequent feature of psychosis 
(Freeman, 2007), and it has been noted that recording in research may increase inhibition (Gelso, 1974). 
Clinicians and researchers often worry about issues such as ‘unblinding’ and audio recording sessions. 
However, these were not found to be problematic in this study. This is in line with previous research in 
which participants expressed no or slight concerns to being recorded and the implementation of audio 
recording in research, practice and clinical training was supported (Briggie et al., 2016). 
Consistent with other research, the main reasons for participating in this study were to improve one’s chance 
of recovery (‘To help myself’), to help others (Schafer et al, 2008) as well as being curious about the 
research. On average there were neutral emotional reactions, positive gains and minimal inconveniences as a 
result of participation. The overall findings appear to echo those of previous research reporting that 
individuals with mental health problems may find participating in a clinical trial a beneficial experience 
(Rosen et al., 2007). Although not all participants felt they were well informed about the research, a majority 
were willing to participate again, very few were motivated by monetary gains and participants rated the 
experience as not at all personally intrusive or harmful.  
4.1. Strengths and limitations  
This study involved individuals with psychosis and contributes to an area of research that is not adequately 
covered in the existing literature (Grant, 2015; Schäfer et al., 2011). It also employed the use of a measure 
that was specifically designed to assess subjective experiences of treatment research and sought to report 
information on its reliability. The addition of an item assessing the consequences of trial ‘blinding’ for the 
participant addresses an important and relevant issue for future trials; something which is currently missing 
in other studies assessing the impact of being involved in a clinical trial.  
However, the study is limited by its relatively small sample size and low response rate for the 12-week 
follow-up questionnaires (55%); therefore these findings may be considered tentative. Participants were 
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asked to complete the additional questionnaires for this sub-study in their own time and without the 
researcher present to avoid bias or coercion. As such participants may have been less likely to return them, 
particularly after completing a lengthy research interview and going through the entire research process. 
This may account for the low response rate for 12-week follow-up data and is a factor which needs further 
consideration in future similar studies. The number of eligible participants who could be approached for this 
study was also reduced due to delays in the ethical approval process.   
The results also reflect the subjective experiences of a selection of participants in the main trial. The 
experience of those who opted not to participate or were not approached for this study remains unknown. 
However no demographic differences were found between participants in the present study and those in the 
larger AVATAR Clinical Trial which helps to demonstrate representativeness in this sample. A further 
caveat is that the sample consists of individuals who were willing to take part in this additional study, and 
therefore might be more willing to accept conditions such as being audio-recorded than those individuals 
who did not agree to take part. Nine out of ten of the individuals who completed both baseline and 12-week 
follow-up questionnaires in this study attended all therapy sessions which can be seen as a further indication 
of willingness to participate and to engage in all aspects of the study.       
The study design ensured participants’ subjective experiences were collected at the earliest opportunity 
following intervention and participants received no further therapy between 12 weeks and 24 weeks follow-
up. While the main avatar trial indicated potential differences in trajectory of treatment response the purpose 
of this study was to assess the subjective experiences of taking part in a clinical trial, including the 
experience of research assessments and exploring benefits of talking about experiences across the recruited 
sample rather than the experience of therapy sessions between arms. A full discussion of the limitations of 
the main AVATAR clinical trial including the absence of a treatment as usual condition and the ‘augmented’ 
form of supportive counselling delivered can be found in the main paper (Craig et al., 2017).  
4.2. Implications and conclusions 
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Considering the substantial commitment required for participating in the AVATAR Clinical Trial and the 
initial concerns of the research team that the assessments and procedures might be somewhat intensive, 
minimal negative impacts were reported overall. The evidence that participation in a clinical trial can be a 
positive and beneficial experience for individuals with mental health problems is important to note in light 
of possible reservations from some clinicians and researchers. Increased self-realisation between baseline 
and 12-week follow-up evaluations suggests that there might be specific personal gains and insight for an 
individual simply through engaging in the research process. Detailed clinical summaries prepared for the 
therapists by the research team were helpful in facilitating this process and may be good practice for similar 
trials.  
The findings also support the view that audio recording of sessions may offer reassurance to some 
participants in that the content and process of the research is being captured objectively (Briggie et al., 
2016). This has implications for its continued use in clinical practice and research. Though difficult and 
traumatic experiences were discussed, negative emotional reactions were rarely elicited and participants felt 
supported throughout the research process. Researchers ensured that the participants felt in control of the 
amount of detail they were comfortable sharing while completing the assessments. These findings may help 
to alleviate concern that participation in similar studies may be personally intrusive or harmful to the 
individuals involved. Discussions around trauma in research assessments might differ in sensitivity to more 
open explorations of abuse occurring in clinical assessments. Therefore the implementation of audio 
recordings requires further exploration in future studies to explore potential differences in its acceptability in 
research and clinical practice.  
Keeping researchers ‘blinded’ to treatment allocation is also a relevant issue for future single blinded 
randomised controlled trials. This issue was approached in the main study by sensitively explaining the 
rationale of ‘blinding’ at each stage of the process to participants (i.e. with researchers at baseline and 
subsequently with the therapist) while recognising that it is inevitable that ‘unblinding’ may occur. It was 
also important to ensure that this did not become a source of concern to the participants in the trial. Although 
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‘unblinding’ occurred in 28 participants (of 150) in the main clinical trial, 25 of those were still happy to 
meet with a different researcher to complete the assessments (Craig et al, 2017).  
In summary, the subjective experiences of individuals in the AVATAR Clinical Trial indicate that 
participants found taking part in the trial a beneficial experience with minimal evidence of a negative 
impact. The findings offer support to previous research and may help to alleviate concern from some 
clinicians and researchers that participation in similar studies may be personally intrusive or harmful. 
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Table 1: Participants’ sociodemographic and clinical characteristics* 
  Range Mean (SD) 
Age  30-72 44.34 (9.87) 
 % N 
Gender 
 
Male 
Female 
65 
32.5 
26 
13 
Ethnicity  
 
White British  
Black British  
Black Caribbean 
Black African 
Asian Indian  
Asian Chinese  
Other 
30 
20 
10 
7.5 
5 
2.5 
20 
12 
8 
4 
3 
2 
1 
8 
18 
 
Diagnosis Paranoid Schizophrenia  
Schizoaffective Disorder  
Bipolar Disorder  
Unspecified non-organic psychosis 
Schizophrenia unspecified  
Depression with psychotic symptoms 
67.5 
15 
5 
2.5 
2.5 
2.5 
27 
6 
2 
1 
1 
1 
Marital Status Single  
Divorced or Separated 
Married/cohabiting  
72.5 
17.5 
5 
29 
7 
2 
 
Employment Working full-time 
Working part-time 
Not working  
2.5 
7.5 
85 
1 
3 
34 
 
Education Higher education qualification/degree 
Vocational qualification  
A Levels 
GCSE/O level/CSE  
No formal qualifications 
17.5 
17.5 
15 
25 
20 
7 
7 
6 
10 
8 
*Note: Data missing for two participants (5%) on all characteristics (except gender); data missing for one participant (2.5%) for 
gender due to questionnaires being returned anonymised.  
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Table 2: Baseline and 12-Week Follow-up Ratings by Participants on the Impact of Participating in 
the AVATAR Clinical Trial 
AIR Item          Baseline          12-Week Follow-up 
Positive Impacts
 a
 
Self-realisation promoted by questionnaire
 
 
Therapy facilitated by questionnaire   
Therapy facilitated by interviews
 
  
Helpfulness of interviews
 
  
Overall positive impact of research
 a
   
Therapy facilitated by research participation 
Personally helped by research participation     
 
Negative Impacts
 a
 
Negative experience of questionnaire
 
  
Irrelevance of interviews
 
  
Disruptiveness of interviews  
Intrusiveness of interviews 
 
Overall negative impact of research
 a
   
Therapy interfered by research participation 
Intrusiveness and harmful effects  
 
Impact of audiotaping 
Difficulty adjusting to audiotaping
 a
 
Comfort level with audiotaping vs. note taking
 
a
 
Time to adjust to audiotaping
 b
 
Experience as helpful or reassuring
 a
   
Mean 
2.76 
3.25 
2.93 
3.13 
 
-- 
-- 
 
                    
1.5 
1.77 
1.24 
2.13 
 
-- 
-- 
 
 
1.43 
2.2 
1.97 
2.82 
 
SD 
1.16 
0.7 
0.86 
0.89 
 
-- 
-- 
 
 
0.9 
1.12 
0.58 
1.14 
 
-- 
-- 
 
 
0.77 
1.32 
1.03 
1.09 
Mean 
3.18 
2.6 
3.07 
3.13 
 
2.5 
3.24 
 
 
1.72 
1.71 
1.06 
1.88 
 
1.39 
1.47 
 
 
-- 
-- 
-- 
-- 
SD 
1.31 
1.18 
0.96 
1.15 
 
1.21 
1.03 
 
 
1.07 
1.1 
0.25 
1.11 
 
0.85 
0.94 
 
 
-- 
-- 
-- 
-- 
a
 Rated on a scale from 1 to 4 (1 = none/not at all; 2 = slightly; 3 = moderately; 4 = considerably) 
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b 
Rated on a scale from 1 to 4 (1 = right away; 2 = very soon; 3 = most of the session; 4 = never did feel 
comfortable) 
 
 
 
 
Table 3: Baseline and 12-Week Follow-up Endorsements for each item 
 Baseline Endorsements (%) 12-Week Follow-up Endorsements (%)
 
AIR Item Not 
at 
all 
Slightly Moderately Considerably Not 
at 
all 
Slightly Moderately Considerably 
Positive Impacts 
Self-realisation 
promoted by 
questionnaire
 
 
Therapy facilitated 
by questionnaire   
Therapy facilitated 
by interviews
 
  
Helpfulness of 
interviews
 
  
 
Overall positive impact 
of research
 
   
Therapy facilitated 
by research 
participation 
 
20.7 
3.6 
7.1 
6.5 
 
 
-- 
-- 
 
 
70 
61.3 
82.8 
36.7 
 
 
17.2 
3.6 
17.9 
12.9 
 
 
-- 
-- 
 
 
16.7 
12.9 
10.3 
33.3 
 
 
27.6 
57.1 
50 
41.9 
 
 
-- 
-- 
 
 
6.7 
12.9 
6.9 
10 
 
 
34.5 
35.7 
25 
38.7 
 
 
-- 
-- 
 
 
6.7 
12.9 
-- 
20 
 
 
17.6 
20 
6.7 
12.5 
 
 
25 
5.9 
 
 
61.1 
64.7 
93.8 
52.9 
 
 
-- 
33.3 
20 
18.8 
 
 
31.3 
23.5 
 
 
16.7 
11.8 
6.3 
17.6 
 
 
29.4 
13.3 
33.3 
12.5 
 
 
12.5 
11.8 
 
 
11.1 
11.8 
-- 
17.6 
 
 
52.9 
33.3 
40 
56.3 
 
 
31.3 
58.8 
 
 
11.1 
11.8 
-- 
17.6 
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Personally helped by 
research 
participation     
 
Negative Impacts 
Negative experience 
of questionnaire
 
  
Irrelevance of 
interviews
 
  
Disruptiveness of 
interviews  
Intrusiveness of 
interviews  
 
Overall negative 
impact of research
 
 
Therapy interfered by 
research participation 
Intrusiveness and 
harmful effects  
 
Impact of audiotaping 
Difficulty adjusting 
to audiotaping
 
 
Comfort level with 
audiotaping vs. note 
taking
 
 
Time to adjust to 
audiotaping 
a 
 
 
-- 
-- 
 
 
70 
50 
43.3 
14.3 
 
 
 
 
 
 
-- 
-- 
 
 
20 
6.7 
26.7 
25 
 
-- 
-- 
 
 
6.7 
16.7 
20 
25 
 
-- 
-- 
 
 
3.3 
26.7 
10 
35.7 
 
77.8 
76.5 
 
 
-- 
-- 
-- 
-- 
 
11.1 
5.9 
 
 
-- 
-- 
-- 
-- 
 
5.6 
11.8 
 
 
-- 
-- 
-- 
-- 
 
5.6 
5.9 
 
 
-- 
-- 
-- 
-- 
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Experience as helpful 
or reassuring
 
 
 
a 
Rated as 1 = right away; 2 = very soon; 3 = most of the session; 4 = never did feel comfortable. 
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Table 4: Descriptive statistics for the RRPQ subscales at 12-Week Follow-up (N = 18*) 
RRPQ Subscale Mean SD Possible 
range 
Sample range 
Participation  
Personal Benefits 
Global Evaluation  
Perceived Drawbacks  
Emotional Reaction  
4.25 
4.13 
4.51 
2.04 
3.12 
0.66 
0.84 
0.5 
0.85 
1.13 
1 - 5 
1 - 5 
1 - 5 
1 - 5 
1 - 5 
 
2.75 - 5 
1.5 - 5 
3.6 - 5 
1 – 3.33 
1 - 5 
 
* One case omitted due to missing data.  
 
 
 
 
 
Highlights 
 Positive and beneficial experience for people with mental health problems  
 Specific personal gains and insight through engaging in the research process  
 Audio recordings may offer reassurance - content and process captured objectively 
 Potential to explore audio recording acceptability in research & clinical practice 
 Consequences of trial ‘blinding’- an important and relevant issue for future trials 
